Jemperli expands indication to all endometrial cancers
By Whang, byung-woo | translator Alice Kang
24.12.11 05:12:49
가나다라
0
Confirms improvement in overall survival in the RUBY study with Jemperli combination therapy
Shows a 31% lower risk of death across all patient populations...median overall survival is 44.6 months
Passes CDDC review as a first-line treatment for advanced or recurrent dMMR/MSI-H endometrial cancer in October
Jemperli's (dostarlimab) indication was expanded to include its use as a first-line treatment in combination with platinum-based chemotherapy for all patients with advanced or recurrent endometrial cancer.
The drug is expected to further expand its influence, with the Health Insurance Review and Assessment Service's Cancer Disease Deliberation Committee passing the drug’s use as first-line treatment of advanced or recurrent dMMR/MSI-H endometrial cancer in combination with platinum-based chemotherapy in October.
▲Pic of Jemperli
On the 10th, GSK Korea announced that it had received approval from the Ministry of Food and Drug Safety (MFDS) to expand Jemperli’s indication to include all patients with ad
Whang, byung-woo(tuai@dailypharm.com)
If you want to see the full article, please JOIN US (click)